Recent Updates
Recently added Catalysts

MK0359

Phase 2

Pulmonary Disease, Chronic Obstructive | Small molecule | Other |Merck & Company, Inc.|Last Updated: Dec 2, 2015

Success Probability
Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
Premium
Market & Valuation
rNPV $3.2B
Market Size $9.4B
Revenue Basis $1.6B
Competitors 6
Premium
Trial Design
RandomizedDouble-BlindUNCONTROLLEDBiomarker
Total Trials1
Total Enrollment45
FDA Designations
No designations recorded
Clinical Trials (1)
NCT IDTitlePhaseStatusEnrollmentVelocityDesignStartCompletionLast UpdatedSitesCountries
NCT00482235A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)PHASE2 COMPLETED 45Dec 1, 2002Apr 1, 2003Dec 2, 2015 -
Unlock Drug Trial Details
Study Design & Arms
AllocationRANDOMIZED
MaskingDOUBLE
ModelPARALLEL
PurposeTREATMENT
Interventions
NameTypeDescription
MK0359DRUG -
Unlock Study Design Details
Eligibility Criteria
Age Range40 Years — 75 Years
SexALL
Healthy VolunteersNo

Inclusion Criteria: * You are between the ages of 40 and 75 * You have had a history for at least a year of COPD symptoms * You have a history of smoking one pack of cigarettes per day for 10 years Exclusion Criteria: * You have been in a research study with an investigational drug or vaccine in ...

Unlock Eligibility Criteria